FILTER
FILTERED INTERVIEW RESULTS
Eduardo Denyer Angel
PRESIDENT, BRENNTAG LATIN AMERICA NORTH
Brenntag is growing rapidly in Mexico through aquistions and increasing market share and penetration.
Fernando Gutiérrez
PRESIDENT, MEXICAN COLLEGE OF CIVIL ENGINEERS (CICM)
Mexico is upgrading its infrastructure, offering opportunities for steel producers and construction firms alike.
Stefan Lepecki
CEO, BRASKEM IDESA
"We work very closely with Pemex and are very confident in their ability."
Cristhian Perez & Ralf van der Ven
VOPAK
“Typically, we see elections as times of uncertainty. However, in the coming year we do not expect a huge impact on the business environment since our business relies on short or long-term positions for basic products.”
J. Rogelio Garza Garza
UNDERSECRETARY OF INDUSTRY AND COMMERCE, MINISTRY OF ECONOMY
The Undersecretary of Industry and Commerce explains its policies towards driving growth for Mexico’s steel industry.
Ricardo Diogo
DIRECTOR BUSINESS DEVELOPMENT, OILTANKING MEXICO
Oiltanking plans to operate two terminals in Tuxpan on the Gulf Coast that will import fuels within 18 months.
Eugenio Gerardo Manzano Alba
EXECUTIVE DIRECTOR, POCHTECA
Pochteca plans to grow organically above the rate of GDP growth and through acquisitions.
Mauricio Morales
GENERAL MANAGER, GALVAPRIME
Galvaprime explains the market for supplying metals to Mexico’s manufacturing sector.
José Luis Uriegas
CEO, GRUPO IDESA
Grupo Idesa has adjusted to Mexico’s energy reforms and is exploring opportunities upstream.
Edison Terra Filho
EXECUTIVE VICE PRESIDENT, BRASKEM
Braskem's five year investment plan includes a new 450,000 kt/y US PP asset and a firm commitment to develop renewables.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
